Home›US Markets›M&A & Deals›Samsung Biologics makes $1.8 billion all-cash bid for…

Samsung Biologics makes $1.8 billion all-cash bid for PolyPeptide

The offer values PolyPeptide at 1.46 billion Swiss francs, or about $1.8 billion, and is structured as an all-cash transaction.

Reported · Written up by our desk · M&A & Deals

Samsung Biologics has made an all-cash bid for Switzerland-based PolyPeptide Group, according to CNBC Markets. The proposed deal is for 1.46 billion Swiss francs, which CNBC World reported as equivalent to about $1.8 billion.

Samsung Biologics said the offer is 100% cash, reflecting a fully cash transaction structure for the acquisition.

More like this

Sources